|
covid-19 |
22 |
|
sars-cov-2 |
14 |
|
anosmia |
10 |
|
olfactory dysfunction |
10 |
|
smell impairment |
10 |
|
acute infection |
8 |
|
convalescent |
8 |
|
dendritic cell |
8 |
|
early |
8 |
|
high-risk |
8 |
|
interferon beta-1b |
8 |
|
remdesivir |
8 |
|
intensive care unit |
6 |
|
antibodies, neutralizing - blood |
5 |
|
female |
5 |
|
immunotherapy - methods |
5 |
|
influenza a virus, h1n1 subtype - immunology - isolation and purification - pathogenicity |
5 |
|
influenza, human - mortality - therapy - virology |
5 |
|
plasma - immunology |
5 |
|
afterload |
4 |
|
extracorporeal membrane oxygenation |
4 |
|
left ventricular systolic function |
4 |
|
transthoracic echocardiography |
4 |
|
adolescent |
3 |
|
adult |
3 |
|
age distribution |
3 |
|
anti-bacterial agents |
3 |
|
aspergillosis - immunology - microbiology |
3 |
|
attitude to health |
3 |
|
bacteremia - diagnosis - drug therapy - epidemiology |
3 |
|
beta-lactamases - metabolism |
3 |
|
cardiac arrest |
3 |
|
cardiogenic shock |
3 |
|
cardiopulmonary resuscitation |
3 |
|
case volume |
3 |
|
case-control studies |
3 |
|
china - epidemiology |
3 |
|
cohort studies |
3 |
|
confidence intervals |
3 |
|
cross-sectional study |
3 |
|
drug therapy, combination - therapeutic use |
3 |
|
ecmo |
3 |
|
escherichia coli - enzymology - isolation & purification |
3 |
|
escherichia coli infections - diagnosis - drug therapy - epidemiology |
3 |
|
extracorporeal membrane oxygenation (ecmo) |
3 |
|
follow-up studies |
3 |
|
hemoglobin |
3 |
|
humans |
3 |
|
immunity, active |
3 |
|
immunity, natural |
3 |
|
incidence |
3 |
|
intensive care unit (icu) |
3 |
|
length of stay (los) |
3 |
|
lung diseases, fungal - immunology - microbiology |
3 |
|
male |
3 |
|
microbial sensitivity tests |
3 |
|
mortality |
3 |
|
multivariate analysis |
3 |
|
myocardial strain |
3 |
|
neurologic outcomes |
3 |
|
pcrto |
3 |
|
pneumocystis - immunology |
3 |
|
prediction |
3 |
|
probability |
3 |
|
red blood cell transfusion |
3 |
|
retrograde |
3 |
|
risk factors |
3 |
|
sex distribution |
3 |
|
speckle tracking echocardiography |
3 |
|
survival rate |
3 |
|
target blood flow |
3 |
|
treatment outcome |
3 |
|
veno-arterial ecmo |
3 |
|
weaning |
3 |
|
antidiabetic agent |
2 |
|
apache iv |
2 |
|
benchmarking |
2 |
|
biguanide |
2 |
|
citrate accumulation |
2 |
|
global longitudinal strain |
2 |
|
hematology |
2 |
|
hong kong |
2 |
|
intensive care |
2 |
|
lactate kinetics |
2 |
|
lactic acidosis |
2 |
|
laundry |
2 |
|
linens |
2 |
|
medicine & public health |
2 |
|
metformin |
2 |
|
metformin-associated lactic acidosis |
2 |
|
oncology |
2 |
|
outbreak |
2 |
|
poisoning |
2 |
|
regional citrate anticoagulation |
2 |
|
rhizopus microsporus |
2 |
|
sepsis |
2 |
|
sepsis-induced myocardial dysfunction |
2 |
|
septic cardiomyopathy |
2 |
|
septic shock |
2 |
|
serum citrate level |
2 |
|
serum lactate level |
2 |
|
speckle tracking imaging |
2 |
|
standard mortality ratio |
2 |
|
strain |
2 |
|
toxicology |
2 |
|
zygomycosis |
2 |
|
acute kidney injury |
1 |
|
asia-pacific |
1 |
|
case report |
1 |
|
doripenem |
1 |
|
hemofiltration |
1 |
|
medical resource utilisation |
1 |
|
renal replacement therapy |
1 |
